Kidneys in space. Sugar in space. Two unrelated headlines from the same week that assemble themselves into an uncomfortably on-brand pipeline: kidneys, sugar, the precursors to diabetes, and eventually — dialysis. In space. Which means, naturally, we're going to need intergalactic health insurance.
I've been ready since 2019, when I pitched a healthcare plan to Emperor Palpatine. PalpiCare: Healthcare for the Galaxy. He seemed receptive.
Article One · Regenerative Medicine
A California biotech company 3D-printed living kidney and liver tissue aboard the ISS in June — the first time either tissue type has been manufactured off Earth — and researchers say microgravity produced unusually uniform cell distribution, a real technical edge over Earth-bound bioprinting.
Who: Auxilium Biotechnologies (Los Angeles), using cell/tissue designs from Wake Forest Institute for Regenerative Medicine (WFIRM)
Where: International Space Station, AMP-1 orbital bioprinter, June 2026
Funding/conflicts: Privately held commercial biotech; statements come from company press release and WFIRM's director — both have a direct financial/reputational stake in the technology succeeding
Company snapshot: Auxilium's actual core business is NeuroSpan Bridge™, a nerve-repair implant now in human clinical trials (first patient enrolled May 2025). "In-Space Biomanufacturing" is listed on their own site as coming soon — the space program is R&D and PR runway for a future orbital manufacturing platform, not yet a product line.
What Happened
The AMP-1 bioprinter produced kidney, liver, and cartilage tissue plus 28 nerve-repair implants in a single ISS mission — the first time one device has manufactured multiple tissue types and finished medical products in one flight. Samples returned to Earth via SpaceX Dragon on June 17. WFIRM director Anthony Atala highlighted that the microgravity environment yielded notably even cell distribution, which on Earth is undercut by gravity-driven settling during printing. This builds on Auxilium's earlier ISS milestone (first medical devices bioprinted in space, Feb 2025, a NASA/InSPA-supported mission).
Strengths
Builds on a real prior milestone (first medical devices bioprinted in space, Feb 2025); independent validation via WFIRM, a legitimate academic regenerative-medicine institute; company already has a nerve-regeneration device (NeuroSpan Bridge™) in human clinical trials.
Weaknesses
This is a press release, not a peer-reviewed paper — no published data on tissue viability, function, or how "uniform cell distribution" was measured. "Kidney and liver tissue" almost certainly means small-scale constructs, not anything resembling a transplantable organ. Timeline to clinical relevance is unstated.
Bottom line
Take it seriously as a manufacturing milestone, with a large grain of salt on "breakthrough" — this is proof-of-concept for space-based biofabrication, not a step change in organ transplant supply.
Article Two · Astrochemistry
Astronomers detected erythrulose — a genuine sugar molecule, the kind found on Earth in raspberries — drifting in a nebula near the galactic center, the first sugar ever confirmed in interstellar space, and a strong clue that the chemical building blocks of life can assemble before stars or planets even exist.
Who: Izaskun Jiménez-Serra (Center for Astrobiology, Spain) and collaborators; published in Nature Astronomy, July 13, 2026
Method: Two radio telescopes trained on the Milky Way's center, matching interstellar radio-frequency signatures to lab spectra of known molecules
Funding/conflicts: Academic astrochemistry consortium; independently reviewed by MIT and Tohoku University researchers not involved in the study — no apparent commercial stake
What Happened
Sugar is essential for life but its origin on Earth has been a real puzzle — lab attempts to synthesize it under plausible early-Earth conditions keep failing, fueling the theory that sugar arrived via asteroid/comet impacts rather than forming here. This study shows the sugar could have formed even earlier, in interstellar ices, before our solar system existed. The team estimates 0.5–50 million tons of erythrulose could have hit early Earth. Independent experts (MIT's Brett McGuire, Tohoku's Yoshihiro Furukawa, who previously found sugars on asteroid Bennu) backed the finding after the team ruled out other molecular matches.
Strengths
Peer-reviewed (Nature Astronomy); multiple independent experts corroborated the spectral match; team explicitly tested and excluded alternative molecular explanations; consistent with prior detections of RNA/DNA precursor molecules in the interstellar medium.
Weaknesses
Detection of one molecule in one nebula — not yet shown to be common galaxy-wide. The team unexpectedly did not find a simpler, related sugar they'd have predicted to see alongside it, which the authors themselves say "defies expectations" and isn't yet explained.
Bottom line
Take it seriously — solid, peer-reviewed, independently vetted — as a genuine step in understanding life's chemical origins, while remembering it's one detection, not proof of a mechanism.